A phase 1b dose expansion study of the pan-Class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

PURPOSE: We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based chemotherapy in patients with advanced solid tumors. The combination was well tolerated and promising preliminary efficacy was observed in PTEN deficien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Smyth, Lillian M., Monson, Kelsey R., Jhaveri, Komal, Drilon, Alexander, Li, Bob T, Abida, Wassim, Iyer, Gopa, Gerecitano, John F., Gounder, Mrinal, Harding, James J., Voss, Martin H., Makker, Vicky, Ho, Alan L., Razavi, Pedram, Iasonos, Alexia, Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Erinjeri, Joseph P., Katabi, Nora, Fury, Matthew G., Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5591764/
https://ncbi.nlm.nih.gov/pubmed/28281183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0445-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados